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inflammatory drug therapy on the incidence of malignancy taken into account.
The unique availability of private patient records
covering a period of over 26 years with examination in
all instances being done by either of two rheumatologists, plus long term follow-ups averaging over four
years, provided an opportunity for a definitive study
of the incidence of malignancy in patients with rheumatoid arthritis. These patients were controlled by
carefully matched patients without rheumatoid arthritis, though suffering from a variety of arthritic disorders such as degenerative arthritis and gout.

In view of the fact that rheumatoid arthritis is considered to be a disturbance of the immune mechanism
(Lawrence, 1965), we thought it seemed reasonable
to direct a study of possible correlation with malignant
diseases, which are also possibly related to immune
mechanism disturbances. Calabro (1967), Lansbury
(1953), Litman, et al (1966), and MacKenzie and
Scherbel ( 1963) have reported the appearance of malignancy accompanying the development of polyarthritis. Calabro (1967) emphasized the importance
of arthritis as a diagnostic warning of occult cancer.
Ragan and Synder (1955) noted that 2 per cent
of 374 patients with rheumatoid arthritis, followed for
more than five years, developed malignancy. However,
he made no comparison to matched controls. Lansbury (1953) collected six cases of collagen disease
which occurred in patients suffering from malignancy.
MacKenzie and Scherbel ( 1963) studied the musculoskeletal symptoms of visceral malignancy in 77
patients. Only 18 of these had arthropathy, and the
symptoms ranged from mild arthralgia to progressive
polyarthritis. No rheumatoid nodules were present, and
rheumatoid factor was present in only one patient.
Miller (1967) studied 17 patients with malignant
lymphomas associated with a variety of so-called "immune diseases" such as rheumatoid arthritis, systemic
lupus erythematosus (SLE), ataxia-telangiectasia, vasculitis, nephrotk syndrome, and dermatomyositis. He
concluded that the same individual may be susceptible
to both types of disease. In addition, Miller ( 1967)
searched for cases of connective tissue disease in 1893
patients with solid malignant tumors and found 11.
Eight were classified as rheumatoid arthritis, one as
SLE, and one each as dermatomyositis and vasculitis.
Among the 264 patients with lymphoproliferative neoplasms, only one case of rheumatoid arthritis was recognized among the five having diffuse connective tissue
disease.
In none of these studies were the patients and the
control population matched for age and socioeconomic
status, nor was the possible influence of anti-

Materials and Methods
A survey of the private patient files over a 26 year
period showed 196 patients with rheumatoid arthritis
whose ages were between 50 and 74 (mean age 60.3) .
These selected charts were carefully reviewed. There
were 106 females and 90 males. The observation
period ranged from one month to 24 years with a mean
of 49.5 months. These patients had either classic or
definite rheumatoid arthritis, according to the criteria
of the American Rheumatism Association (Ropes,
1958). A rigorous selection resulted in loss of over 50
per cent of the patients orginally thought to have rheumatoid arthritis. For comparison, charts of 125 patients
with arthritis of a non-rheumatoid type-degenerative
joint disease, primary gout, non-specific tendinitis, and
psoriatic arthritis-and of the same age group (mean
age 60.5) were reviewed. There were 72 females and
53 males. The observation period ranged from one
month to 20 years with a mean of 56.8 months. ~n
older age group was selected for both groups on the
premise that the higher incidence of malignancies in
this advanced age group would tend to make the results more valid in the relatively small number of
patients. Cases of hypertrophic pulmonary osteoarthropathy were excluded from the study. All patients
were, or had been, on the private service and in the
middle or upper classes. Each patient had a complete
history and physical examination performed, and those
who were followed longer than one month had periodic complete examinations.
Laboratory studies performed on all patients included hemoglobin, white blood count and differential,
erythrocyte sedimentation rate (Wintrobe), urinalysis,
serum uric acid and rheumatoid pattern (latex flocculation, sensitized human cell, and sensitized sheep cell
tests). Methods used include those previously described
by Waller et al ( 1961) , and the Venereal Disease Research Laboratory test (VDRL). If systemic lupus
erythematosus was suspected, one or more LE cell
tests were performed. t Appropriate X-ray studies were
also performed on each patient.

* Supported by Public Health Service Research Grant
AM 04549. This is publication number 30 from the Charles
C. Thomas Arthritis Fund.

t Patients with positive LE cell tests were excluded from
the study.
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Results

A total of eight patients out of 196 with rheumatoid
arthritis had systemic malignancies. Table 1 summarizes
the main features of these cases. All cases had significant titers of rheumatoid factor. Six of the eight cases
were receiving adrenocorticosteroid preparations at
the time the malignancy was diagnosed, and all six
had taken an equivalent of 5-10 mg of prednisone
daily for over one year.

A total of five out of 125 patients with arthritis of a
non-rheumatoid type were discovered to have systemic
malignancies. Table 2 summarizes the main features of
these cases. None had rheumatoid factor or were receiving adrenocorticosteroids.
Discussion

Correspondence with 12 clinicians throughout the
nation, specializing in the treatment of connective
tissue diseases, revealed that the majority felt that

TABLE 1
Summary of 8 patients with systemic malignancies discovered in a study of 196 patients with rheumatoid arthritis in the
50-74 age group.
Patient

Age

Sex

1. A.M
2. H.L.

74
63

F
M

3. D.S.
4. E.P.

68
68

5. L.H.

Malignancy

Long term
Rheumatoid Factor
Length ofR A
prior to maligsteroids
nancy (years) Latex SHC*
SSC** (>12mos.)
8

+
+

1 : 80
1 : 2048

4
17

+
+

10

11

F
M

Carcinoma of stomach
Transitional cell
carcinoma of urinary
bladder
Carcinoma of breast
Carcinoma of lung

65

F

Carcinoma of breast

6. R.M.

51

M

Acute lymphatic
leukemia

7. C.T.

74

M

8. H.R.

50

M

Comments

Yes
No

Metastatic disease
Metastatic disease

1 : 1280 1 : 320
1 : 640 1 : 160

Yes
No

1 : 1280 1 : 160

Yes

4

+
+

1 : 640

1 : 160

Yes

Lymphosarcoma,
reticulum cell type

4

+

1 : 640

1 : 40

Yes

Carcinoma of lung

4

+

1 : 320

1· : 160

Yes

Metastatic disease
Steroids- discontinued
6 yrs before development of malignancy
Peripheral neuropathy
present
Pt. had not received
phenylbutazone for 3
yrs
Terminal development
of stem cell leukemia
Pt. had taken phenylbutazone intermittently including
period several wks
prior to discovery of
lymphoma
Metastatic disease

1 : 2048

* Sensitized Human Cell

* * Sensitized Sheep Cell

TABLE 2
Summary of 5 patients with systemic malignancies discovered in a study of 125 patients with arthritis of a non-rheumatoid
type in the 50-74 age group.
Patient

Age

1. M.B.

66
55
52
70
71

2. F.C.

3. J.G.
4. E.H.
5. J.K.

Sex
F
M
M
F
M

Malignancy
Carcinoma of colon
Adenocarcinoma of kidney
Carcinoma of prostate
Carcinoma of breast
Chronic granulocytic leukemia

Type of Arthritis
Degenerative joint disease
Gout
Degenerative joint disease
Degenerative joint disease
Gout (onset 20 years prior to diagnosis of leukemia)
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systemic malignancies were quite rare in cases of rheumatoid disease. Ragan and Snyder ( 1955) , however,
believed the incidence to be the same as in the general
population .
Rheumatoid disease was diagnosed an average of 94
months prior to the onset of systemic malignancy in
our eight cases. We did not observe the apparent
malignancy-induced polyarthritis such as was described
by MacKenzie and Scherbel ( 1963) .
Essentially no difference ( 4 per cent of each group)
was noted in the incidence of malignancies in the rheumatoid and non-rheumatoid groups. However, in the
rheumatoid group a case of lymphosarcoma (reticulum
cell type) with terminal state of stem-cell leukemia, and
a case of acute lymphatic leukemia was noted among
the eight cases of malignancy. The patient with lymphosarcoma (C. T.) had taken either phenylbutazone
(Butazolidin®) or oxyphenbutazone (Tandearil®) on
an intermittent basis for approximately 40 months
after the onset of rheumatoid arthritis. The patient reinstituted phenylbutazone several weeks prior to the
discovery of lymphosarcoma. He did not have Sjogren's
syndrome, an association noted by Talal (1966). The
patient with the leukemia (R. M.) had not received
phenylbutazone for three years prior to the discovery
of the leukemia. A cause-effect relationship between
these drugs and leukemia has been suggested by
Fraumeni (1967) .
Although Miller ( 1967) reported a statistically significant difference between the incidence of diffuse connective tissue disease in patients with solid tumors
(0.58 per cent) and patients with malignant lymphomas ( 1.86 per cent), a review of his data shows no
difference in incidence for the two groups of malignancies when the disease rheumatoid arthritis is considered by itself. Among his 264 patients with lymphoproliferative neoplasms there were five patients with
connective tissue diseases, but only one had rheumatoid
arthritis while two had dermatomyositis.
Hench (1962) found 22 cases of diffuse connective
tissue disease in a study of 1000 cases of lymphoma
(2.2 per cent), but the diffuse connective tissue diseases
were not further divided into specific diseases. In a
pension study in Great Britain, .L ea (1964) noted a
6.5 per cent incidence of "rheumatic" disease in cases
of lymphoproliferative disease, in contrast to 1.5 per
cent in a control population. However, once again
the rheumatic diseases were defined as all those conditions presently classified under this heading, with
the exception of arthritis following trauma. The diagnoses were derived from hospital records. Lea ( 1964)
concluded that there was a very definite association
between the reticuloses and the "rheumatic" diseases.
Jn Miller's study of immune disease and malignant
lymphoma (1967) , there was no overall pattern to
suggest a cause-effect relationship.
It is noted that six of our 13 patients ( 46.1 per
10

cent) with malignancy had taken adrenocorticosteroids
on a long-term basis. However, only 51 of the 308
patients ( 16.5 per cent) without malignancy had received this therapy. This is a significant difference
(Pis < 0.007).
This carefully directed study suggests that among
patients in the age range of 50 to 74 years, malignancy
may be more closely associated with steroid therapy
than it is with the disease rheumatoid arthritis .
Summary
A retrospective study of the incidence of rheumatoid
arthritis and systemic malignancy was performed using
the records of 196 older age patients with classic or
definite rheumatoid arthritis. The results were compared to 125 patients in the same age group who had
arthritis of a non-rheumatoid type. There was no difference in the incidence of malignancy in the two
groups of patients. However, there was a positive
correlation between the incidence of malignancy and
the use Qf long term adrenocorticosteroid therapy .
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